title: [Diagnosis and treatment for plasma cell leukemia].
authors.affiliation: Division of Hematology, Department of Internal Medicine, Bureau of Advanced Medicine and Hemato-Oncology, National Center for Global Health and Medicine.
authors.forename: Akiyoshi
authors.initials: A
authors.lastname: Miwa
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D003520:Cyclophosphamide / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage / Q000031:analogs & derivatives; D005938:Glucocorticoids / Q000008:administration & dosage; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D000077269:Lenalidomide; D007952:Leukemia, Plasma Cell / Q000175:diagnosis* / Q000628:therapy*; D008558:Melphalan / Q000008:administration & dosage; D011719:Pyrazines / Q000627:therapeutic use; D000069283:Rituximab; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D001897:Boronic Acids; D005938:Glucocorticoids; D011719:Pyrazines; C004180:dexamethasone 21-phosphate; D000069283:Rituximab; D013792:Thalidomide; D000069286:Bortezomib; D003907:Dexamethasone; D003520:Cyclophosphamide; D000077269:Lenalidomide; D008558:Melphalan